No Clinically Significant Drug Interaction Between Trazodone and Wegovy
There is no documented or clinically significant drug interaction between trazodone and Wegovy (semaglutide). Based on the FDA drug label and available pharmacokinetic data, semaglutide has minimal potential for drug-drug interactions through standard metabolic pathways.
Pharmacokinetic Evidence
Semaglutide demonstrates very low potential for drug interactions because:
- No CYP enzyme interactions: In vitro studies show semaglutide has very low potential to inhibit or induce cytochrome P450 enzymes 1
- No transporter inhibition: Semaglutide does not inhibit drug transporters 1
- Minimal metabolic interference: The primary elimination route is proteolytic cleavage and beta-oxidation, not hepatic metabolism that would compete with other drugs 1
- High protein binding: Over 99% albumin-bound, which limits interactions 1
Gastric Emptying Consideration
The only mechanistically relevant concern is semaglutide's effect on gastric emptying, which could theoretically affect absorption of oral medications 1. However:
- Trazodone is typically well-absorbed regardless of gastric emptying rate
- FDA testing at semaglutide 1 mg steady-state showed no clinically relevant effects on co-administered oral medications including metformin, warfarin, digoxin, atorvastatin, and oral contraceptives 1
- At the 2.4 mg dose (Wegovy), no apparent effect on gastric emptying rate was observed in separate studies 1
Clinical Bottom Line
You can safely prescribe trazodone and Wegovy together without dose adjustments or special monitoring for drug interactions. The only documented trazodone interaction of note is with warfarin 2, which is unrelated to semaglutide therapy.
Practical Monitoring
While no interaction exists, monitor patients for: